Sorafenib and 2-Deoxyglucose Synergistically Inhibit Proliferation of Both Sorafenib-Sensitive and -Resistant HCC Cells by Inhibiting ATP Production

Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related deaths globally. Sorafenib is the only first-line systemic drug for advanced HCC, but it has very limited survival benefits because patients treated with sorafenib either suffer from side effects or show disease progressio...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Gene Expr
Autori principali: Reyes, Ryan, Wani, Nissar A., Ghoshal, Kalpana, Jacob, Samson T., Motiwala, Tasneem
Natura: Artigo
Lingua:Inglês
Pubblicazione: Cognizant Communication Corporation 2016
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5296238/
https://ncbi.nlm.nih.gov/pubmed/27938509
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3727/105221616X693855
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi